Trial Profile
CT-2103 [paclitaxel poliglumex] vs Docetaxel for the Second-Line Treatment of Non-Small Cell Lung Cancer (NSCLC): A Phase III Study
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2020
Price :
$35
*
At a glance
- Drugs Paclitaxel poliglumex (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms STELLAR-2
- Sponsors CTI BioPharma
- 02 Oct 2020 Status changed from completed to discontinued.
- 26 Jul 2007 Status change
- 04 Sep 2005 New trial record.